Read More

Annexon Announced Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications; Said Well-Capitalized with Operating Runway into 2025

Annexon, Inc. (Nasdaq: ANNX) today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

ANNX

Read More

Merus Announced Based On The Company’s Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities, Expected To Fund Merus’ Operations Into Second Half 2025

Merus N.V. (Nasdaq: MRUS) today provided its 2023 outlook. - As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy - Petosemtamab clinical update planned for first half of 2023

MRUS